The novel vitamin D analog ZK191784 inhibits prostate cancer cell invasion

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4091-4098

  Stio, Maria ^a   Martinesi, Maria ^a   Simoni, Antonella ^a   Zuegel, Ulrich ^b   Steinmeyer, Andreas ^b   Santi, Raffaella ^a   Treves, Cristina ^a   Nesi, Gabriella ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BAYER PHARMA AG   (Germany)

Author keywords

Adhesion molecules; MMP 2; MMP 9; Prostate cancer; Vitamin D analog; ZK191784

Indexed keywords

CALCITRIOL; GELATIN; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; ZK 191784;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INCUBATION TIME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

CALCITRIOL; CELL LINE, TUMOR; DENSITOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84855184070     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Gronberg H: Prostate cancer epidemiology. Lancet 361: 859-864, 2003.
3. So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9, 2005. (Pubitemid 40425164)
4. Jodele S, Blavier L, Yoon JM and Declerck YA: Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 25: 35-43, 2006. (Pubitemid 43723980)
5. Zucker S, Lisk RM, Zarrabi MH and Moll U: M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993. (Pubitemid 23019389)
6. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
7. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006. (Pubitemid 43723979)
8. Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89, 2004. (Pubitemid 39592897)
9. Daja MM, Niu X, Zhao Z, Brown JM and Russel PJ: Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis 6: 15-26, 2003. (Pubitemid 36432616)
10. Hubbard A and Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 28: 1379-1386, 2000. (Pubitemid 30623498)
11. Liu AY, Rudier MP and True LD: Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165: 1543-1556, 2004. (Pubitemid 39435154)
12. Hayes SH and Seigel GM: Immunoreactivity of ICAM-1 in human tumors, metastasis and normal tissues. Int J Clin Exp Pathol 2: 553-560, 2009.
13. Klein EA: Chemoprevention of prostate cancer. Crit Rev Oncol Hematol 54: 1-10, 2005.
14. Stewart LV and Weigel NL: Vitamin D and prostate cancer. Exp Biol Med (Maywood) 229: 277-284, 2004. (Pubitemid 38372891)
15. Schwartz GG, Wang MH, Zhang M, Singh RK and Siegal GP: 1αa,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6: 727-732, 1997. (Pubitemid 27427629)
16. 3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 27: 32-42, 2006.
17. Ahonen MH, Tenkanen L, Teppo L, Hakama M and Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847-852, 2000.
18. Corder EH, Guess HA, Hulka BS, Friedman GD, Salder M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH and Orentreich N: Vitamin D and Prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467-472, 1993.
19. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141: 2548-2556, 2000.
20. 3 as therapeutic agents for prostate cancer. Clin Cancer Res 6: 901-908, 2000.
21. 3 analog with reduced hypercalcemic activity. J Invest Dermatol 119: 1434-1442, 2002.
22. Strauch UG, Obermeier F, Grunwald N, Dunger N, Rath HC, Schölmerich J, Steinmeyer A, Zügel U and Herfarth HH: Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulphate-induces colitis by modulation of intestinal dendritic cell numbers and phenotype. World J Gastroenterol 13: 6529-6537, 2007.
23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
24. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
25. Beer TM and Myrthue A: Calcitriol in cancer treatment: from the lab to the clin. Mol Cancer Ther 3: 373-381, 2004. (Pubitemid 39193713)
26. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 11: 221-229, 2000.
27. Meyer T and Hart IR: Mechanisms of tumor metastasis. Eur J Cancer 34: 214-221, 1998.
28. Gross C, Stamey T, Hancock S and Feldman D: Treatment of early recurrent prostate cancer with 1α,25-dihydroxy vitamin D3 (calcitriol). J Urol 159: 2034-2039, 1998.
29. Zhuang SH, Schwartz GG, Cameron D and Burnstein KL: Vitamin D receptor and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126: 83-90, 1997. (Pubitemid 27055550)
30. Chung LW, Baseman A, Assikis V and Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20, 2005. (Pubitemid 39627663)
31. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP and Schwartz SA: Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 64: 5311-5321, 2004. (Pubitemid 39006551)
32. Yin Y, Ni J, Chen M, Guo Y and Yeh S: RRR-α-Vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side-effects. Clin Cancer Res 15: 190-200, 2009.
33. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack J and Brooks J: Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63: 187-197, 2005. (Pubitemid 40525367)
34. Berry LJ, Au GG, Barry RD and Shafren DR: Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate 68: 577-587, 2008. (Pubitemid 351614636)
35. Conrad F, Zhu X, Zhang X, Chalkley JR, Burlingame AL, Marks JD and Liu B: Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer invasion. J Mol Med 87: 507-514, 2009.